HERA-CD27L / Apogenix - LARVOL DELTA

HERA-CD27L, a true CD27 agonist, has superior activity over benchmark agonistic antibodies and induces T cell activation for potent anti-tumor immunity (CIMT 2019) - "As we have shown here, the hexavalent HERA-CD27L has superior activity compared to bivalent antibodies. Altogether, HERA-CD27L shows single-agent anti-tumor efficacy, is well tolerated by multiple relevant species and the lead candidate is currently ready for GMP cell line development."

IO Biomarker • PD(L)-1 Biomarker

HERA-CD27L, a true CD27 agonist, is a hexavalent CD27 ligand that enhances T cell activation and induces potent anti-tumor immunity (AACR 2019) - "As we have shown here, the hexavalent HERA-CD27L has superior activity compared to bivalent antibodies. Altogether, HERA-CD27L shows single-agent anti-tumor efficacy, is well tolerated by multiple relevant species and the lead candidate is currently ready for GMP cell line development."

IO Biomarker • PD(L)-1 Biomarker

Hexavalent Agonists Targeting the TNFR Superfamily for Cancer Immunotherapy (TRICON 2019) - "HERA compounds show single agent anti-tumor activity and provide exciting opportunities for combinatorial treatment. The presentation will focus on data obtained with HERA-CD40L, HERA-CD27L and HERA-GITRL."